Members

o2h Ventures, a specialist biotech fund manager based in the heart of the thriving biotech community in Cambridge, UK. We invest in early-stage biotech companies involved in novel drug discovery, enabling service tools, and AI/ML technologies. Currently, we have two tax-efficient human health funds open for investment: the Enterprise Investment Scheme and the Seed Enterprise Investment Scheme.

To date, through our funds, we have invested over $10 million in 35+ early-stage biotech companies, empowering impactful research addressing unmet medical needs in areas such as cancer, depression, diseases of the ear and eye, psoriasis, idiopathic pulmonary fibrosis, anti-ageing, and infectious diseases. For more details, please see – www.o2hventures.com

Based in London, Oberon Group provides investment services along with strategic planning and advice to growing businesses. We deliver services to private individuals aiming to maximise returns and take advantage of diverse investment opportunities. Our specialist teams work both independently and collaboratively to deliver a dynamic and personalised service to our private and corporate clients. The business is underpinned by traditional values and integrity complemented by 21st century innovation from a proven team accomplished at delivering inspiring ideas and access to unique opportunities and networks.

At Oberon we pride ourselves in offering clients the personal attention of a private office whilst delivering the capabilities, contacts, and services of a much larger institution. Our clients value the entrepreneurial mind-set our dynamic team brings to the table where our services are tailored to a specific individual or business’ needs, and traditional approaches are considered alongside more innovative ideas. The solutions and strategies implemented are as varied as the individuals and businesses that require them.

Octopus is synonymous with small company investing and is the UK’s largest specialist manager of tax efficient investments, managing more than £13bn on behalf of both retail and institutional investors. Our experience spans more than 20 years and, in that time, we have invested over £2 billion in early-stage companies.

Each Octopus Ventures EIS portfolio will have around 10-15 companies selected for their ambitious growth targets and potential to become a household name of the future. Investors will have access to the expertise of Octopus Ventures, one of the largest venture capital teams in Europe. Our previous track record for identifying, growing and exiting some of Britain’s brightest companies includes investments in Graze, Secret Escapes, Zoopla and Tails.com, to name but a few. Our pipeline of opportunities spans very early stage (seed) through to Series A and Series B investments.

We have aligned our fees with the interests of our investors. Our annual management charge is only payable if a company is sold for more than the amount invested into it.

We invest in seed and early stage companies from a range of different industries, with a particular focus on technology. Oxford Capital is one of the most experienced tax-efficient investment managers in the UK. Since pioneering the first EIS funds in 1999, Oxford Capital has been recognised multiple times as Best EIS Fund Manager. We have invested over £400m in small companies across the UK and are proud of partnering with some exceptional founders. Our current portfolio includes some well known brands such as Curve, Moneybox, Push Doctor, Spoke and more.  More information can be found at www.oxcp.com.